Table 3.
Efficacy evaluation of MS patients at 12 mo posttreatment
| M0 | M12 | Change from M0 to M12 | P‐valueb | |
|---|---|---|---|---|
| EDSS | 5.1 (±1.73) | 5 (±1.86) | ‐0.1 (±2.16) | .94 |
| Volume of MRI‐WM lesions (mm3) | 34.5 (±30.3) | 44.7 (±32.9) | 10.2 (±17.5) | .04 |
| Number of B MRI‐WM lesions | 130 (±91) | 134 (±96) | 4.3 (±7.01) | .10 |
| Number of SC MRI‐WM lesions | 14.3 (±5.2) | 14.4 (±5.3) | 0.1 (±0.32) | .99 |
| Number of enhanced MRI‐WM lesions | 5.5 (±11.2) | 1.5 (±1.96) | ‐4 (±9.38) | .78 |
| VEPa (ms) | 127.3 (±23.4) | 127.5 (±26.3) | 0.22 (±7.25) | .84 |
| OCTa μm | 85.2 (±15.3) | 84.4 (±16.29) | ‐0.8 (±4.15) | .69 |
| 9‐hole peg test (s) | 32.2 (±5.19) | 29.9 (±4.66) | ‐2.31 (±3.08) | .06 |
| T25FW test (min) | 12.6 (±10.2) | 11.5 (±9.1) | ‐1.1 (±11.2) | .62 |
| MMSE | 29.1 (±.73) | 29 (±3.16) | ‐0.1 (±1.97) | .98 |
Worst eye measurement (right or left).
Wilcoxon paired test.
T25FW, Timed 25‐Foot Walk; MMSE, Mini‐Mental Status Examination; EDSS, Extended Disability Status Scale; WM, white matter; VEP, visual evoked potential; OCT, optical coherence tomography; R, right; L, left; M, month, s, seconds, ms, milliseconds.